Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. reported promising Phase 2b clinical trial results for PrimeC, showing a significant slowing of ALS progression, and is preparing for a Phase 3 trial in the U.S. with FDA discussions planned for Q3 2024. Financially, the company has maintained stable R&D and general expenses, securing $4.5 million through a recent financing and transitioning to U.S. GAAP accounting standards. The CEO expressed optimism for the future, citing strong clinical evidence and upcoming milestones that could lead to an NDA submission.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
